EUS-Guided Ablation for Pancreatic and GI Lesions Registry
Official title: Prospective Observational Registry of EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions
Run by West Virginia University · NCT07625189 · Data updated 2026-11-12
This registry collects real-world data on adults undergoing EUS-guided RFA or MWA to treat pancreatic or other GI lesions during routine care to see how these treatments affect lesion size, survival, and symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | West Virginia University Academic / other |
| Locations | 1 site (Morgantown, West Virginia) |
| Status | Recruiting |
| Started | March 10, 2026 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | June 4, 2026 |
| Trial ID | NCT07625189 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older with a pancreatic premalignant lesion or malignancy or other GI/hepatobiliary lesion for which EUS-guided ablation is planned as part of routine care.
✕Probably not a fit
Patients who are not candidates for or do not undergo follow-up imaging and clinical assessments may not derive direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, investigator-initiated prospective registry that follows adults receiving endoscopic ultrasound-guided radiofrequency or microwave ablation for pancreatic and other gastrointestinal/hepatobiliary lesions as part of standard care. Data are drawn from medical records and clinical systems without changing how patients are managed. Primary outcomes include changes in lesion size on imaging and overall survival after ablation; secondary outcomes cover tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms. The study will help characterize long-term clinical experiences with these ablation techniques in routine practice.
Why it matters
Potential benefit: If successful, the registry could improve understanding of real-world safety and effectiveness of EUS-guided ablation for GI lesions and help guide future research and patient care.
How similar studies have gone: Previous observational work with ablation approaches has shown variable but informative results; this registry aims to add real-world data from a dedicated center.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥ 18 years of age. * Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care. * At least one clinically identified target lesion for which RFA or MWA is performed. Exclusion Criteria: * In the judgment of the treating clinician, inclusion in the registry would not be appropriate * The individual is expected to be unable to complete routine clinical follow-up.
Where it's running
-
West Virginia University
Morgantown, West Virginia, United States Recruiting
Study contacts
- Principal investigator: Shailendra Singh, MD — West Virginia University
- Study coordinator: Zim Warda Hasan
- Email: zh00027@mix.wvu.edu
- Phone: 364-203-1900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of Anesthesia on Inflammation and NETosis During HCC Ablation
This study tests whether a propofol–fentanyl anesthesia plan with lidocaine during radiofrequency ablation for hepatocellular carcinoma affects inflammation and NETosis in patients with small tumors.
-
Electroporation versus Radiofrequency Ablation Guided by 3D Imaging for Repeat Atrial Fibrillation
This trial tests whether pulsed field electroporation or standard radiofrequency ablation works better and safer for people having a repeat catheter ablation for recurrent atrial fibrillation.
-
Pulsed field ablation registry for atrial arrhythmias in Poland.
This project will collect information to see how well pulsed field ablation works and how safe it is for people in Poland having ablation for atrial fibrillation, atrial flutter, or atrial tachycardia.
-
Microwave ablation for papillary thyroid microcarcinoma monitored with contrast-enhanced ultrasound and genetic testing
This project will try microwave ablation guided by contrast-enhanced ultrasound and an 88-gene panel in adults with low-risk papillary thyroid microcarcinoma to see if it controls the tumor while preserving thyroid function.
-
Gastric ablation therapy for weight management after stopping GLP-1 medications
This study tests if a procedure called gastric ablation can help adults keep off weight they lost with GLP-1 medications after they stop taking them.
-
Using donafenib after thermal ablation for recurrent liver cancer
This study is testing if adding a low dose of donafenib after thermal ablation can help people with early recurrent liver cancer do better than just having the ablation alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.